To: (10)(2e) [(10)(2e) @rivm.nl]; (10)(2e) [(10)(2e) @rivm.nl]; (10)(2e) [(10)(2e) @rivm.nl]; (10)(2e) (10)(2e) [(10)(2e) @rivm.nl]; (10)(2e) [(10)(2e) @rivm.nl]; (10)(2e) [(10)(2e) @rivm.nl]; (10)(2e) [(10)(2e) @rivm.nl]
From: (10)(2e)
Sent: Mon 11/9/2020 1:35:05 PM
Subject: Re: FFX T cell
Received: Mon 11/9/2020 1:35:06 PM

Hi (10)(2e)

Symptom data is only available for the first-time point for now as (10)(2e) informed me

Best,

(10)(2e)

From: (10)(2e)
Sent: Monday, 9 November 2020 13:02:19
To: (10)(2e); (10)(2e); (10)(2e); (10)(2e) (10)(2e); (10)(2e); (10)(2e); (10)(2e)
Subject: RE: FFX T cell

Also might consider to run the different timepoints separately, or did you already do that?

From: (10)(2e) < (10)(2e) @rivm.nl>
Sent: maandag 9 november 2020 11:19
To: (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>
Subject: RE: FFX T cell

Hi (10)(2e)

Thanks for your response, yes hopefully the deep phenotyping data will improve separation of the groups *

Groeties,
(10)(2e)

From: (10)(2e) < (10)(2e) @rivm.nl>
Sent: maandag 9 november 2020 11:10
To: (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>
Subject: Re: FFX T cell

Hi (10)(2e)

Yes I did that too but it did not improve the separation. When we run the deep phenotyping pipeline hopefully that will help!

Best,

(10)(2e)

From: (10)(2e)
Sent: Friday, 6 November 2020 15:55:44
To: (10)(2e) ; (10)(2e) ; (10)(2e) ; (10)(2e) ; (10)(2e) ; (10)(2e) ; (10)(2e)
Subject: RE: FFX T cell

Hi (10)(2e)

Good work, although it is a pity of course that you don't see any difference.
Did you include both children and adults in this analysis?
If so, do you also see no difference between symptoms/without symptoms among adults only?

Best regards,
(10)(2e)

From: (10)(2e) < (10)(2e) @rivm.nl>
Sent: vrijdag 6 november 2020 15:37
To: (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>
Subject: Re: FFX T cell

Hi all,

I ran the PCA and random forest to see the differences between people with and without symptoms in trucounts

(10)(2e) sent me the symptom status of T1 samples. I took all the PCR+ T1 and ran the analysis. The random forest did not find a significant difference between symp+ and symp-. As you can also see in PCA, based on trucount data there was no clear separation either.

Best,
(10)(2e)

From: (10)(2e)
Sent: Tuesday, 3 November 2020 09:19:37
To: (10)(2e) ; (10)(2e) ; (10)(2e) ; (10)(2e) ; (10)(2e) ; (10)(2e) ; (10)(2e)
Subject: RE: FFX T cell

Hi all,

I added several manuscripts to the folder "literature" (on T cells and (in separate subfolder) more general/other immunity).

One manuscript (see attachment) I already wanted to send to you, it describes a study that compared the immunity to SARS-CoV-2 (incl. T cell activation) between children and adults with mild to moderate clinical manifestations, comparable to our study design.

Best regards,

(10)(2e)

From: (10)(2e) < (10)(2e) @rivm.nl>
Sent: maandag 2 november 2020 20:12
To: (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>
Subject: RE: FFX T cell

Hi all,

Thanks for meeting on this short notice. Great to agree that data that we have is quite unique, and feedback for some further analyses to make it stronger.

As promised the link to folder for
All literature R:\Projecten\ZZZ0034 FFX Studie\13. Laboratories\13.7 FFX cellular assays\1. Literature
And the **paper layout** R:\Projecten\ZZZ0034 FFX Studie\14. Reports\FFX T cell paper_1

Best wishes
(10)(2e)

-----Original Appointment-----
From: (10)(2e)
Sent: donderdag 29 oktober 2020 10:06
To: (10)(2e); (10)(2e); (10)(2e); (10)(2e); (10)(2e); (10)(2e); (10)(2e); (10)(2e); IIV-teleconference2
Cc: (10)(2e)@gmail.com'
Subject: FFX T cell
When: maandag 2 november 2020 16:00-17:00 (UTC+01:00) Amsterdam, Berlijn, Bern, Rome, Stockholm, Wenen.
Where: GtM: 820-484-925

Hi all,

Now that all T-cell data has been analyzed, it would be good to discuss next steps and how to start writing this up.
I attached the talk I gave last Monday, which contains most analyses. All data can be found here:
R:\Projecten\ZZZ0034 FFX Studie\13. Laboratories\13.7 FFX cellular assays\T-cell ELISPOT

Best,
(10)(2e)

FFX T cell (10)(2e)